Bharat Biotech's Covaxin demonstrates 81% interim efficacy in its phase 3 trial.Read other #coronavirus updates: https://t.co/JNjmAvJ2UG pic.twitter.com/P63U5qKI96— NDTV Profit (@NDTVProfitIndia) March 3, 2021
Bharat Biotech's Covaxin demonstrates 81% interim efficacy in its phase 3 trial.Read other #coronavirus updates: https://t.co/JNjmAvJ2UG pic.twitter.com/P63U5qKI96